Who Paid My Doc
Plegridy (peginterferon 1a) Real World Effectiveness and Safety Observational Program
Research payments
$111,169
Through program year 2023, $111,169 in research payments was reported against Plegridy (peginterferon 1a) Real World Effectiveness and Safety Observational Program, across 37 payments, paid by Biogen, Inc..
- Paid by
- Biogen, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $1,055 | 3 |
| 2022 | Research | $110,114 | 34 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Joanna Cooper Berkeley, CA Named on 2 payments
- Lawrence Goldstick Dayton, OH Named on 1 payment
- Gregory Wu Saint Louis, MO Named on 1 payment
- Jeffrey English Atlanta, GA Named on 1 payment
- Robert Charlson New York, NY Named on 1 payment
- Jacob Sloane Boston, MA Named on 1 payment
- Stanley Cohan Portland, OR Named on 1 payment
- Bridget Bagert New Orleans, LA Named on 1 payment
- Carlo Tornatore Washington, DC Named on 1 payment
- Gabriel Pardo Oklahoma City, OK Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.